Quarterly Results

202601 Results Summary

Revenue

The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Operating Profit

Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

PBDT

PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Profit Before Tax

Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Net Profit

Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Company News

More

Earnings

CategoryQ1 FY25-26Q1 FY24-25Change %FY24-25FY23-24Change %
Total Revenue3,264.443,244.180.6213,321.7411,813.1012.77
Expenses3,007.152,655.9713.2211,343.1811,518.72-1.52
Other Income26.4431.49-16.04113.721,237.32-90.81
Operating Profit84.6771.0719.142,092.281,531.7036.60
Depreciation129.93117.7910.31486.01581.91-16.48
Interest58.2339.5847.12207.07515.97-59.87
Profit Before Tax95.57462.33-79.331,399.21433.82222.53
Tax48.60122.09-60.19382.341,115.55-65.73
Net Profit370.10340.278.771,047.14-1,433.52-173.05
CategoryQ1 FY25-26Q4 FY24-25Change %
Total Revenue3,264.443,256.200.25
Expenses3,007.153,068.00-1.98
Other Income26.4411.69126.18
Operating Profit84.6778.408.00
Depreciation129.93125.213.77
Interest58.2366.71-12.71
Profit Before Tax95.577.971099.12
Tax48.603.591253.76
Net Profit370.10377.47-1.95

Research Reports

ActionTarget Price (₹)BrokerDateReports
Data Not Found

Financial Reports

Data not available.

Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Data Not Found

Corporate Information

Company News

Glenmark Pharma to launch Ropivacaine Hydrochloride Injection USP in US

The product is approved as bioequivalent and therapeutically equivalent to the reference listed drug, Naropin Injection, marketed by Fresenius Kabi USA LLC

Updated On: 23 Oct 2025 | 7:04 PM IST

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Updated On: 26 Sep 2025 | 9:13 AM IST

Why Nomura continues to back Glenmark Pharma; Retains 'Buy'; Find out here

Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.

Updated On: 25 Sep 2025 | 12:04 PM IST

Stocks to Watch today, Sept 25: Polycab, Waaree Energies, Akzo, Tata Steel

Stocks to Watch today, September 25, 2025: From Polycab to Akzo Nobel, here is a list of stocks that will be in focus today

Updated On: 25 Sep 2025 | 7:43 AM IST

Glenmark Pharma signs $18 mn deal with Hengrui for cancer therapy drug

The agreement gives Glenmark exclusive rights to develop and commercialise cancer drug Trastuzumab Rezetecan outside China, the US, Europe, and other select markets

Updated On: 24 Sep 2025 | 8:48 PM IST

Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal

Glenmark shares rose 3% after confirming receipt of $700 million from AbbVie under a global licensing deal for ISB 2001, with milestone payments of up to $1.2 billion

Updated On: 09 Sep 2025 | 8:10 PM IST

Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn

The buying on the counter came after the company's subsidiary Ichnos Glenmark Innovation received an upfront payment of $700 million from AbbVie

Updated On: 09 Sep 2025 | 10:50 AM IST

Glenmark Pharma up 3% on DCGI nod to start phase 3 trial of Envafolimab

Around 11:20 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 3.05 per cent at ₹2,051.40 per share. In comparison, BSE Sensex was trading 0.25 per cent lower at 80,518.51 levels.

Updated On: 05 Sep 2025 | 11:23 AM IST

These three stocks are a must-have in your portfolio; top reasons here

Markets edged higher and gained over half a percent, supported by optimism surrounding the GST Council meeting.

Updated On: 04 Sep 2025 | 7:29 AM IST

Don't miss out on these 2 stocks, say analysts at MOFSL; details inside

Recently Nykaa stock had given a breakout on the weekly charts with high volumes. In last few days the stock gradually moved higher and showed relative strength when the markets were correcting.

Updated On: 04 Sep 2025 | 7:10 AM IST
More